[1]郑辉,胡睿.左心室辅助装置对心肌能量代谢及胰岛素抵抗的影响[J].国际内分泌代谢杂志,2023,43(04):317-320.[doi:10.3760/cma.j.cn121383-20220312-03028]
　Zheng Hui,Hu Rui.Effect of left ventricular assist device on myocardial energy metabolism and insulin resistance[J].International Journal of Endocrinology and Metabolism,2023,43(04):317-320.[doi:10.3760/cma.j.cn121383-20220312-03028]
点击复制

左心室辅助装置对心肌能量代谢及胰岛素抵抗的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年04期
页码:
317-320
栏目:
综述
出版日期:
2023-07-20

文章信息/Info

Title:
Effect of left ventricular assist device on myocardial energy metabolism and insulin resistance
作者:
郑辉; 胡睿
天津大学泰达国际心血管病医院内分泌科,天津 300457
Author(s):
Zheng Hui;  Hu Rui
Department of Endocrinology, TEDA International Cardiovascular Hospital, Tianjin University, Tianjin 300457, China
关键词:
左心室辅助装置;  终末期心力衰竭;  心肌能量代谢;  血糖;  胰岛素抵抗
Keywords:
Left ventricular assist device;  Advanced heart failure;  Myocardial energy metabolism;  Blood glucose;  Insulin resistance
DOI:
10.3760/cma.j.cn121383-20220312-03028
摘要:
慢性心力衰竭患者的心肌细胞代谢途径由脂肪酸氧化向糖酵解转换,这种转换是对心肌缺氧的生理适应性反应,同时伴有胰岛素抵抗和生长激素/胰岛素样生长因子-1抵抗,最终出现各种能量代谢障碍。左心室辅助装置(left ventricular assist device,LVAD)是一种新的改善终末期心力衰竭患者生活质量和生存率的治疗方法。大量研究证实,LVAD能够改善心肌细胞能量代谢,上调糖酵解、磷酸戊糖途径和单碳糖代谢途径,减轻氧化应激及炎性反应,改善胰岛素抵抗。LVAD植入初期和远期都能显著改善高血糖患者的血糖水平,但是多数研究显示血糖改善与预后无关,可能需要从单纯控糖转向糖尿病的全面管理。
Abstract:
The metabolic pathway of cardiomyocytes in patients with chronic heart failure is converted from fatty acid oxidation to glycolysis, which is a physiological adaptive response to myocardial hypoxia. This transition is accompanied by insulin resistance,which lead to various energy metabolic disorders eventually. Left ventricular assist device(LVAD)is a new treatment method that improves the quality of life and survival rate in patient with end-stage heart failure. A large number of studies have confirmed that LVAD can improve energy metabolism and up-regulate glycolysis, pentose phosphate pathway and single carbon sugar metabolism pathway in cardiomyocyte. Further more, LVAD can improve insulin resistance through reducing oxidative stress and inflammation. LVAD implantation can significantly improve the blood glucose control among hyperglycemia patients in both the initial and long term stage.However, most studies showed the improvement in blood glucose control did not related with the prognosis. It may indicate the necessary of shifting from simple glucose control to comprehensive management of diabetes.

参考文献/References:

[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2020概要[J].中国循环杂志,2021,36(6):521-545.DOI:10.3969/j.issn.1000-3614.2021.06.001.
[2] Teuteberg JJ,Cleveland JC Jr,Cowger J,et al.The society of thoracic surgeons intermacs 2019 annual report:the changing landscape of devices and indications[J].Ann Thorac Surg,2020,109(3):649-660.DOI:10.1016/j.athoracsur.2019.12.005.
[3] Bedi KC Jr,Snyder NW,Brandimarto J,et al.Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure[J].Circulation,2016,133(8):706-716.DOI:10.1161/CIRCULATIONAHA.115.017545.
[4] Yang CD,Pan WQ,Feng S,et al.Insulin resistance is associated with heart failure with recovered ejection fraction in patients without diabetes[J].J Am Heart Assoc,2022,11(19):e026184.DOI:10.1161/JAHA.122.026184.
[5] Erqou S,Adler AI,Challa AA,et al.Insulin resistance and incident heart failure:a meta-analysis[J].Eur J Heart Fail,2022,24(6):1139-1141.DOI:10.1002/ejhf.2531.
[6] Uddin GM,Zhang L,Shah S,et al.Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure[J].Cardiovasc Diabetol,2019,18(1):86.DOI:10.1186/s12933-019-0892-3.
[7] Zheng L,Li B,Lin S,et al.Role and mechanism of cardiac insulin resistance in occurrence of heart failure caused by myocardial hypertrophy[J].Aging(Albany NY),2019,11(16):6584-6590.DOI:10.18632/aging.102212.
[8] Salzano A,Marra AM,D'Assante R,et al.Growth hormone therapy in heart failure[J].Heart Fail Clin,2018,14(4):501-515.DOI:10.1016/j.hfc.2018.05.002.
[9] Consolo F,Barberini L,Fattuoni C,et al.Metabolomic profile of patients with left ventricular assist devices:a pilot study[J].Ann Cardiothorac Surg,2021,10(2):240-247.DOI:10.21037/acs-2020-cfmcs-117.
[10] Nguyen AB,Imamura T,Besser S,et al.Metabolic dysfunction in continuous-flow left ventricular assist devices patients and outcomes[J].J Am Heart Assoc,2019,8(22):e013278.DOI:10.1161/JAHA.119.013278.
[11] Scheiber D,Zweck E,Jelenik T,et al.Reduced myocardial mitochondrial ROS production in mechanically unloaded hearts[J].J Cardiovasc Transl Res,2019,12(2):107-115.DOI:10.1007/s12265-018-9803-3.
[12] Shahinian JH,Rog-Zielinska EA,Schlimpert M,et al.Impact of left ventricular assist device therapy on the cardiac proteome and metabolome composition in ischemic cardiomyopathy[J].Artif Organs,2020,44(3):257-267.DOI:10.1111/aor.13566.
[13] Badolia R,Ramadurai DKA,Abel ED,et al.The role of nonglycolytic glucose metabolism in myocardial recovery upon mechanical unloading and circulatory support in chronic heart failure[J].Circulation,2020,142(3):259-274.DOI:10.1161/CIRCULATIONAHA.119.044452.
[14] Hilse MS,Kretzschmar T,Pistulli R,et al.Analysis of metabolic markers in patients with chronic heart failure before and after LVAD implantation[J].Metabolites,2021,11(9):615.DOI:10.3390/metabo11090615.
[15] MacDonald MR,Petrie MC,Hawkins NM,et al.Diabetes,left ventricular systolic dysfunction,and chronic heart failure[J].Eur Heart J,2008,29(10):1224-1240.DOI:10.1093/eurheartj/ehn156.
[16] Goetz ME,Charnigo R,Guglin M.Implantation of left ventricular assist device results in immediate improvement of glucose metabolism in patients with and without diabetes mellitus[J].Heart Lung Circ,2020,29(6):931-935.DOI:10.1016/j.hlc.2019.05.181.
[17] Patel N,Gluck JA,Radojevic J,et al.Left ventricular assist device implantation improves glycaemic control:a systematic review and meta-analysis[J].ESC Heart Fail,2018,5(6):1141-1149.DOI:10.1002/ehf2.12337.
[18] Diakos NA,Taleb I,Kyriakopoulos CP,et al.Circulating and myocardial cytokines predict cardiac structural and functional improvement in patients with heart failure undergoing mechanical circulatory support[J].J Am Heart Assoc,2021,10(20):e020238.DOI:10.1161/JAHA.120.020238.
[19] Khan RS,Kato TS,Chokshi A,et al.Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure:correction after ventricular assist device implantation[J].Circ Heart Fail,2021,5(6):340-348.DOI:10.1161/CIRCHEARTFAILURE.111.964031.
[20] Riehle C,Abel ED.Insulin signaling and heart failure[J].Circ Res,2016,118(7):1151-1169.DOI:10.1161/CIRCRESAHA.116.306206.

备注/Memo

备注/Memo:
通信作者:郑辉,Email:zhui0123@163.com
更新日期/Last Update: 2023-08-15